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Abstract: This paper focuses on genomic predictive biomarkers in medicine. It is known that 
single nucleotide polymorphisms of genes involved in the pathogenesis of various diseases, 
including cancer, can serve as indicators of risk warranting further diagnostics, screening, and 
early prevention measures. However, although ten million single nucleotide polymorphisms 
have been identified to date, the majority of them do not appear to have a relationship with 
risk of development of pathogenic processes in the human body. The concept of selection of 
significant disease-associated biomarkers is proposed. Also, future development of integrative 
systems of genomic risk markers is discussed.
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Genomic biomarkers in medicine
One of the most hazardous public health problems is cancer. More than seven million 
deaths from cancer were registered worldwide in 2008.1 However, annual death rates 
have been decreasing slowly since 1990 in men and since 1991 in women.1 This prog-
ress is largely as a result of intensive development of modern preventative measures 
against cancer, the efficiency of which is growing every year. Obviously, prevention 
of a disease is much easier than its treatment, and so the problem of cancer prevention 
is one of the most basic issues when combating the burden of the disease.
Novel approaches in health care are moving towards the model of “personalized 
medicine”.2 Advances in health care are growing annually, as well as their social 
relevance. Diagnostic tests and targeted therapy have become common. However, in 
spite of novel improvements in screening and prevention modalities, the prognosis of 
patients with many diseases, including cancer, remains poor. Thus, modern molecular 
biology and medicine are concerned with developing more and more novel genomic 
markers with predictive, therapeutic, and prognostic significance.3 Several markers may 
evaluate the predisposition of a given person to one or another disease with a certain 
degree of accuracy based on the results of a simple blood test. Widespread application 
of these tests can reveal risk groups in populations, and thereafter, a complex of pre-
ventive measures among risk-group subjects may be conducted. Moreover, the above-
mentioned genomic markers can be identified in the perinatal period, so the choice 
between “include” or “not to include” in the risk group on the basis of these systems 
can be made very early, and, consequently, preventive measures can have maximal 
efficacy. As a result, integrative systems of predictive genomic markers, once defined, 
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will allow future generations to be informed and forewarned 
about their risks of and predispositions to certain diseases.
Therefore, discovery and development of predictive, 
therapeutic, or prognostic markers is the primary problem of 
biomedicine at the present time. However, the critical barrier 
to progress in this field is that it is not always easy to find 
an effective genomic marker that is specifically associated 
with a particular disease.3 One of the most widespread and 
important genomic markers is the single nucleotide polymor-
phism, which represents a variation in DNA sequence, when 
a single nucleotide differs between members of a biological 
species or paired chromosomes in an individual. The presence 
of such a substitution in DNA sequence may often cause a 
deviation of protein function and/or lead to disruption of 
exonic splicing enhancer sequences.4 Single nucleotide poly-
morphisms may lead to changes in transcription factors and 
vary the efficiency of gene expression, as well as introduce 
an alternative translation initiation codon that may lead to 
downregulation of the wild-type transcript.4 It is known that 
single nucleotide polymorphisms can cause instability of 
exonic mRNA as well.5 Because they often have relatively 
substantial functional consequences and a potentially high 
incidence in a population, single nucleotide polymorphisms 
can be very informative and are extensively used in studies 
of their association with risk for many diseases, including 
cancer. Hence, it is feasible to say that identification of single 
nucleotide polymorphisms as markers of cancer predisposi-
tion is a convenient, simple, and effective way to identify 
and treat various malignancies in the earliest stages.
Over ten million single nucleotide polymorphisms have 
been identified to date, and the majority of them may not 
have any association with risk of occurrence or features of 
development of pathogenic processes in the human body.6 
Therefore, a major question arises as to which genes and 
which polymorphisms should be selected for further inves-
tigation of their possible associations with cancer. It is nec-
essary to mention briefly the major families of proteins and 
enzymes for which genes and functional single nucleotide 
polymorphisms are currently being investigated for their 
association with cancer risk.
Antioxidant defense system
A great number of carcinogens promote the generation 
of so-called reactive oxygen species, which cause dam-
age to DNA and may therefore lead to development of 
cancer. DNA damage caused by reactive oxygen species 
is termed “oxidative stress”. The most common reactive 
oxygen species are superoxide radicals, hydroxide radicals, 
peroxyl radicals, nitric oxide, alkoxyl radicals, and hydrogen 
peroxide. Nevertheless, human cells are protected against 
oxidative stress by an interacting network of antioxidant 
enzymes, including catalases, superoxide dismutases, 
glutathione peroxidases, peroxiredoxins, paraoxonases, and 
many others. The role of these enzymes is to break down 
dangerous reactive compounds before they reach a strand of 
DNA. Hence, effective and proper functioning of antioxidant 
defense enzymes is the first barrier to carcinogens entering 
the living cell.
DNA repair system
In spite of antioxidant defense enzymes, the genome of 
each human cell acquires more than one million molecular 
lesions every day.7 Protection of cells against accumula-
tion of numerous mutations is carried out by DNA repair 
enzymes. These enzymes are able to recognize single-strand 
and double-strand breaks and repair them. Moreover, DNA 
repair enzymes correct the erroneous insertion, deletion, and 
misincorporation of bases that occurs during the recombina-
tion and replication of DNA. Thereby, DNA repair enzymes 
maintain a more or less stable state of the genome, and the 
rate of successful DNA repairs reflects the best chances for 
the cell to avoid occurrence of an oncogenic mutation.
Apoptotic pathways
In the event that accumulation of DNA damage becomes 
large due to severe stress, or the DNA repair system is poor, 
the cell then undergoes so-called programmed cell death 
or apoptosis. Apoptosis occurs because some cells become 
cancerous owing to the large amount of accumulated errors. 
Because they pose a potential threat to the organism, it is 
better to kill them for the better good. Thereby, in the context 
of cancer, apoptosis greatly decreases the likelihood of a cell 
becoming cancerous.8 Initiation of apoptosis is controlled 
by numerous regulatory and adaptor proteins, which are 
activated by various intracellular and/or extracellular signals. 
It is known that inhibition of apoptosis plays an important 
role in the development of cancer.9 Moreover, mutations in 
cycle-regulating genes, such as ras, c-myc, or p53, may lead 
to development of cancer or a significantly increased cancer 
risk.10–12
Pattern recognition receptors
It is well known that some viruses can induce cancer 
because they carry oncogenes in their genomes.10 In other 
cases, viruses may incorporate their genome near the 
proto-oncogene, putting it under the control of the viral 
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transcriptional promoter.10 In addition, it is necessary to 
note that any infectious agent provoking inflammation can 
initiate cancer as well, because the presence of a prolonged 
inflammatory response is accompanied by severe cellular 
stress, and consequently may lead to accumulation of DNA 
damage, mutations, and eventually promote cancer. Pattern 
recognition receptors directly recognize common antigen 
determinants of virtually all classes of pathogens (so-called 
pathogen-associated molecular patterns) and initiate an 
immune response against them via specific intracellular 
signaling pathways. Pattern recognition receptors include 
families of Toll-like receptors, NOD-like receptors, C-type 
lectin receptors, and RIG-I-like receptors. Their work protects 
the organism from infectious agents and may prevent, inhibit, 
or block carcinogenesis, whilst disrupted functioning of these 
pattern recognition receptors may allow infectious agents 
or tumor cells to avoid recognition by the immune system 
and, consequently, not be eliminated.13 Notably, such pattern 
recognition receptor activation may sometimes promote 
carcinogenesis, creating a proinflammatory microenvironment 
(via the action of respective cytokines) that is favorable for 
tumor progression and development of chemoresistance.13 
Thereby, pattern recognition receptors play a significant role 
in the development of cancer, and maintaining a balance 
between low and high pattern recognition receptor activity 
greatly decreases the risk of a cancer developing.
Immune system
Despite all the above-mentioned mechanisms of protection, 
cancers do occur. When there is a tumor in the organism, the 
only thing that may help is the immune response. There is a 
huge amount of evidence indicating that the immune system 
plays a key role in the battle of the organism against cancer.7,10 
Tumor cells express their own antigens which cause immune 
cells to recognize cancer and eliminate it. However, tumor 
cells often have a reduced number of major histocompatibility 
complex class I molecules on their surface, thus avoiding 
detection by killer T cells.14 The crucial role in anticancer 
defense belongs to cytokines, a diverse multifunctional group 
of proteins that facilitate communication between immune 
cells, control genes, regulate transcription factors, and govern 
the inflammation, differentiation, proliferation, and secre-
tion of antibodies.7 The most important cytokine classes 
are interleukins, interferons, and tumor necrosis factors. It 
is important to note that the harmonious, coordinated, and 
smooth functioning of cytokines in many respects deter-
mines the effectiveness of the anticancer immune response. 
In some cases, incorrect functioning of cytokines (frequently 
caused by underexpression or overexpression of certain 
cytokine genes) directly favors development of cancer. For 
instance, a shift in the balance between the activity of proin-
flammatory and anti-inflammatory interleukins may cause 
prolonged inflammation, and therefore promote neoplastic 
transformation.15,16 Another example is that it is known that 
interleukin-17 possesses strong angiogenic activity due to 
its ability to inhibit angiostasis and enhance secretion of 
angiogenic chemokines; therefore, overexpression of inter-
leukin-17 may contribute significantly to the massive blood 
supply to the tumor.17
In general, all the above-mentioned systems protect 
against the occurrence or progression of cancer in a large 
number of cases, and inherited variations in genes that encode 
the above-named proteins and enzymes are responsible for 
individual susceptibility to cancer. The next question that 
arises is how to select single nucleotide polymorphisms that 
can potentially be associated with cancer?
Concept of selection
Gene polymorphism may be included on the short list for 
further oncogenomic studies if:
•	 Single nucleotide polymorphisms lead to substantial 
functional consequences at the molecular level (eg, it 
strongly affects transcription, splicing, translation, stabil-
ity, and transport of pre-mRNA, mRNA, noncoding RNA, 
or protein encoding by the gene, or noticeably influences 
signaling of synthesized protein)
•	 Single  nucleotide  polymorphism  is  frequent  in 
populations
•	 Functional consequences of the single nucleotide poly-
morphism are significantly associated with a condition 
that substantially increases the risk of cancer due to 
deregulation of systems listed above
•	 Single nucleotide polymorphism is associated with risk 
of cancer in population studies.
Gene polymorphism can also be included on the extended 
list if it is characterized by more subtle functional altera-
tions in the gene that still result in qualitative or quantitative 
alterations of the encoding protein (or noncoding RNA). 
One question that arises immediately is how to distinguish 
“substantial” and more “subtle” functional changes at the 
molecular level? It seems to be difficult to answer this ques-
tion only on the basis of the general principles of molecular 
biology, because even the smallest alteration in the structure 
of one gene may have critical consequences, while for another 
gene the converse can be true. Therefore, an assessment of 
the “power” of functional alteration should be individualized 
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for each gene, and even if conclusions obtained in various 
investigations do differ, these discrepancies would not distort 
the general picture, ie, if the polymorphism has “serious” 
functional consequences according to the results of an iso-
lated study, it should definitely be added to the short list until 
these conclusions are disproven. In any case, the general value 
of creating such short and extended lists of prescriptive poly-
morphisms is that they can overcome the difficulties related 
to these complications. It is important to note that many 
polymorphisms can be simply in linkage disequilibrium with 
truly functional variants, and fundamental investigations are 
needed to determine if they are merely markers of associa-
tion or indeed causal variants. All polymorphisms that are 
only in linkage disequilibrium with functional ones should 
be excluded from both lists.
The results of various population studies devoted to the 
investigation of association between gene polymorphisms 
and cancer may also differ, and possible reasons for these 
disparities include an inadequate sample size, and differ-
ences in age, gender, ethnic, racial, and clinicopathological 
characteristics, in prevalence of the infectious agent rel-
evant to the disease under investigation in cases and control 
groups, in other bacterial, host, or environmental factors, in 
the immune response caused by a specific ligand, in strati-
fication, and in methods of diagnostics of cancer or chronic 
inflammatory conditions, and genotyping methods, as well 
as chance. In addition, studies for which negative results are 
obtained tend not to be published (the so-called “file drawer” 
effect), which may create a significant bias and distort the 
picture observed at the present time.
To distinguish the impact of chronic inflammatory con-
ditions from the contribution of other mechanisms to the 
association between gene polymorphisms and cancer risk, 
stratification of cases and controls by infectious agent status 
and chronic inflammation status should be mandatory in 
future studies devoted to this question. Sample size should 
be sufficient, and this depends on the frequency of the tar-
get polymorphism; if the frequency is high, the sample size 
can be less than in studies where the frequency is low. It is 
also important to note that there are two main components 
determining the importance of single nucleotide polymor-
phisms in integrative systems of genomic risk markers that 
can be used in programs for cancer prevention, ie, the value 
of the odds ratio between cases and controls (in the whole 
population as well as in subgroups) and the prevalence of 
the polymorphism in the population, and both these compo-
nents may vary in different geographic regions. Moreover, 
it is desirable to develop not just one general program, but 
a number of individual programs for different countries, 
populations, and environmental conditions.
Looking into the future
It is certainly true that further investigations of single nucle-
otide polymorphisms will provide new and robust data for 
the molecular epidemiology of cancer. In the event that an 
association between certain single nucleotide polymor-
phisms of and increased or decreased cancer risk is revealed 
and confirmed by various case-control studies in different 
populations, then these polymorphisms should be established 
as valid predictive markers of cancer. In the future, such 
genomic cancer risk markers should be unified in the general 
integrative systems for each cancer type, population, and/or 
subgroups of the population, and should be used in various 
programs for cancer prevention. Generally, these programs 
would consist of the following steps:
•	 Maximal early (perinatal) determination of risk groups 
(high, moderate, and low), and further stratification of 
these risk groups into intermediate categories
•	 Development of preventive measures for these risk 
groups.
In addition, development of an integrative system of 
genomic risk markers would provide a theoretical basis for 
the creation of a specific microchip including all risk fac-
tors, which will greatly simplify determination of cancer 
risk. Furthermore, the above-mentioned concept should be 
true not only for cancer, but also for other human diseases. 
It may also be useful to create an international electronic 
open-access database of short and extended lists of polymor-
phisms of each gene for every disease to stratify prospective 
polymorphisms for genomic investigation. Finally, this strat-
egy may lead to breakthroughs for preventive interventions 
in the field of the molecular epidemiology of cancer and 
other diseases.
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